Please assess the completion status of the following clinical trial:

Trial Title: Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18 years of age or over.~2. Histologically documented diagnosis of malignant GIST.~3. Immunohistochemical documentation of c-kit (CD117) expression either by the primary tumor or metastases using the DAKO assay.~4. Performance status 0,1, 2, 3 (ECOG)~5. Adequate end organ function, defined as the following: total bilirubin \< 1.5 x ULN, SGOT and SGPT \< 2.5 x UNL (or \< 5 x ULN if hepatic metastases are present), creatinine \< 1.5 x ULN, ANC \> 1.0 x 109/L, platelets \> 100 x 109/L.~6. Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 2 weeks (according to updated Invest. Brochure) following discontinuation of study drug.~7. Written, voluntary, informed consent.~Exclusion Criteria:~1. Patient has another malignant tumor in CR\<3 years (except if the other primary malignancy is inactive and not requiring active intervention). Previous basal cell skin cancer or a cervical carcinoma in situ are allowed.~2. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)~3. Female patients who are pregnant or breast-feeding.~4. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.~5. Patients received chemotherapy within 2 weeks prior to study entry, unless the disease is rapidly progressing~6. Patients had a major surgery within 2 weeks prior to entry study~7. Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.~8. Previous treatment with Glivec®

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- interruption of Glivec® (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).